TNFRSF9 and neoplasm: Based on the physiological effects of CD137 against tumors, Lucido et al. found that agonists for CD137 in the HPV (+) HNSCC mouse model had a synergistic effect on inhibiting tumor growth compared to traditional single radiotherapy and chemotherapy.